The Week in Numbers (to the 3rd November)
Harms in healthcare: where’s the common sense when you need it
7,228
As of 28 October 2024, the MHRA has received 7,228 reports of common gastrointestinal reactions, such as nausea, vomiting, and diarrhoea, associated with GLP-1RAs used for weight management. Of these reports, 68 indicated that the individual was hospitalised.
One thing is sure: the number of reports will substantially underestimate the number of adverse events.
1.50
New measures are in place for valproate-medicines
A meta-analysis of data from a retrospective observational study in Denmark, Sweden, and Norway found that children whose fathers were treated with valproate monotherapy in the three months before conception had a pooled adjusted hazard ratio of 1.50 (95% CI: 1.09-2.07) for neurodevelopmental disorders (NDDs) when compared to those in the lamotrigine/levetiracetam monotherapy group.
The NDDs include autism spectrum disorders, intellectual disability, communication disorders, attention deficit/hyperactivity disorders, and movement disorders)
577
The number of Field Safety…
